HSP90 alpha Polyclonal Antibody
| 规格： | / 60μL / 120μL / 200μL |
| 价格： | / ￥1380 / ￥2220 / ￥3300 |
货号：E-AB-70141
宿主: Rabbit
反应性: H,M,R
应用: WB
Overview
| Synonyms | EL52,epididymis luminal secretory protein 52,Heat shock 86 kDa,heat shock 90kD protein 1,alpha,Heat shock 90kD protein 1,alpha like 4,heat shock 90kD protein,alpha-like 4,Heat shock 90kDa protein 1 alpha,Heat shock protein 90kDa alpha (cytosolic) class A member 1,Heat shock protein HSP 90-alpha,HS90A,HSP 86,HSP86,Hsp89,HSP89A,Hsp90,HSP90A,HSP90AA1,HSP90ALPHA,HSP90N,HSPC1,HSPCA,HSPCAL1,HSPCAL4,HSPN,LAP 2,LAP2,lipopolysaccharide-associated protein 2,LPS-associated protein 2,Renal carcinoma antigen NY-REN-38,HSP90 alpha抗体 |
| Swissprot | P07900,P82995,P07901 |
| Source | Rabbit |
| Reactivity | Human,Mouse,Rat |
| Immunogen | KLH conjugated Synthetic peptide corresponding to Mouse HSP90A |
| Application | WB(Detection kit: E-IR-R304) |
| Recommended dilution | WB,,1:500-1:2000; |
| Concentration | 460 μg/mL |
| Clonality | Polyclonal |
Properties
| Cellular localization | Cell membrane, Cytoplasm, Membrane, Nucleus |
| Tissue specificity | Highest expression level in middle temporal gyrus |
| Isotype | IgG |
| Purification | Affinity purification |
| Conjugation | Unconjugated |
| Storage instructions | Store at -20℃. Avoid freeze / thaw cycles. |
| Storage buffer | PBS with 0.02% sodium azide,100 μg/ml BSA and 50% glycerol. |
| Background | HSP90,encoded by HSP90AA1,is a constitutively and ubiquitously expressed molecular chaperone that is crucial for the stability and function of many proteins. HSP90 provides chaperoning activity for client proteins; many of them are members of oncogenic pathways,indicating its implication in tumor malignancy. HSP90 mainly resides in the cytosol,while it can also be released to the extracellular space. Secreted Hsp90 is a C-terminal truncated form. It has been reported that the level of plasma Hsp90 is positively correlated with tumor malignancy in clinical cancer patients,and can be a promising diagnostic marker for tumor malignancy in clinical application. |
